iaso biotherapeutics usa limited
5941 Optical Ct
2 articles with iaso biotherapeutics usa limited
IASO Biotherapeutics announced on Oct 26, 2021 that the Office of Orphan Products Development of the U.S. Food and Drug Administration has granted the Orphan Drug Designation to the company's in-house developed fully human CD19/CD22 dual-targeted chimeric antigen receptor -T cell therapy for the treatment of acute lymphoblastic leukemia.
IASO Biotherapeutics has appointed Dr. Alan Fu as Chief Financial Officer (CFO), reporting to Maxwell Wang, CEO, IASO Bio.